Thomas M. Lancaster
Directeur Technique/Scientifique/R&D chez Akston Biosciences Corp.
Profil
Thomas M.
Lancaster is currently the Director and Vice President of Research & Development at Akston Biosciences Corp.
and a Member at Massachusetts Institute of Technology.
He has previously worked as a Principal at Union Carbide Corp.
and as Vice President of Research & Development at SmartCells, Inc. Lancaster holds a doctorate degree from Massachusetts Institute of Technology and an undergraduate degree from The Pennsylvania State University.
Postes actifs de Thomas M. Lancaster
| Sociétés | Poste | Début |
|---|---|---|
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Akston Biosciences Corp.
 Akston Biosciences Corp. Pharmaceuticals: MajorHealth Technology Akston Biosciences Corp. engages in the development of biologic therapeutics for use in autoimmune Type 1 diabetes prevention. It offers novel vaccine, disrupt insulin autoimmunity to prevent type 1 diabetes, and controlled hypoglycemia to enhance anti-tumor cancer therapy. The company was founded by Todd C. Zion in 2011 and is headquartered in Beverly, MA. | Directeur Technique/Scientifique/R&D | 01/12/2011 |
Anciens postes connus de Thomas M. Lancaster
| Sociétés | Poste | Fin |
|---|---|---|
Union Carbide Corp.
 Union Carbide Corp. Chemicals: Major DiversifiedProcess Industries Union Carbide Corp. engages in the production of chemicals and polymers. The firm operates through the following geographical segments: United States, Asia Pacific and Rest of the World. Its products include polyethylene and polypropylene, ethylene glycol, isopropanol, ethyleneamines, biocides, surfactants, deicing and anti-icing fluids, amines, solution vinyl resins and polyethylene glycols. The company was founded on November 1, 1917 and is headquartered in Seadrift, TX. | Corporate Officer/Principal | - |
SmartCells, Inc.
 SmartCells, Inc. Medical SpecialtiesHealth Technology SmartCells, Inc. develops glucose-regulated smart insulin products for the treatment of diabetes. The company was founded by Todd C. Zion and James M. Herriman in 2003 and is headquartered in Beverly, MA. | Directeur Technique/Scientifique/R&D | - |
Formation de Thomas M. Lancaster
| Massachusetts Institute of Technology | Doctorate Degree |
| The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
SmartCells, Inc.
SmartCells, Inc. Medical SpecialtiesHealth Technology SmartCells, Inc. develops glucose-regulated smart insulin products for the treatment of diabetes. The company was founded by Todd C. Zion and James M. Herriman in 2003 and is headquartered in Beverly, MA. | Health Technology |
Union Carbide Corp.
Union Carbide Corp. Chemicals: Major DiversifiedProcess Industries Union Carbide Corp. engages in the production of chemicals and polymers. The firm operates through the following geographical segments: United States, Asia Pacific and Rest of the World. Its products include polyethylene and polypropylene, ethylene glycol, isopropanol, ethyleneamines, biocides, surfactants, deicing and anti-icing fluids, amines, solution vinyl resins and polyethylene glycols. The company was founded on November 1, 1917 and is headquartered in Seadrift, TX. | Process Industries |
Akston Biosciences Corp.
Akston Biosciences Corp. Pharmaceuticals: MajorHealth Technology Akston Biosciences Corp. engages in the development of biologic therapeutics for use in autoimmune Type 1 diabetes prevention. It offers novel vaccine, disrupt insulin autoimmunity to prevent type 1 diabetes, and controlled hypoglycemia to enhance anti-tumor cancer therapy. The company was founded by Todd C. Zion in 2011 and is headquartered in Beverly, MA. | Health Technology |